Lymphomas constitute the second most common indication for high dose therapy (HDT) followed by autologous hematopoietic cell transplantation (auto-HCT). The intent of administering HDT in these heterogeneous disorders varies from cure (e.g., in relapsed @entity146 ) to disease control (e.g., most @entity706 ). Regardless of the underlying histology or remission status at transplantation, disease relapse remains the number one cause of post auto-HCT therapy failure and mortality. The last decade has seen a proliferation of clinical studies looking at prevention of post auto-HCT therapy failure with various maintenance strategies. The benefit of such therapies is in turn dependent on disease histology and timing of transplantation. In relapsed, chemosensitive @entity1892 ( @entity1892 ), although post auto-HCT maintenance rituximab seems to be safe and feasible, it does not provide improved survival outcomes and is not recommended. The preliminary results with anti- programmed death -1 (PD-1) antibody therapy as post auto-HCT maintenance in @entity1892 is promising but requires randomized validation. Similarly in @entity706 , maintenance therapies including rituximab following auto-HCT should be considered investigational and offered only on a clinical trial. Rituximab maintenance results in improved progression-free survival but has not yet shown to improve overall survival in @entity1073 ( @entity1073 ), but given the poor prognosis with post auto-HCT failure in @entity1073 , maintenance rituximab can be considered on a case-by-case basis. Ongoing trials evaluating the efficacy of post auto-HCT maintenance with novel compounds (e.g., immunomodulators, PD-1 inhibitors, proteasome inhibitors and bruton's @entity4149 kinase inhibitors) will likely change the practice landscape in the near future for B cell non- @entity978 @entity1 following HDT and auto-HCT.

Recent advances in post autologous transplantation maintenance therapies in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity706 :: ('MESH:D008223', 'Disease') :: ['indolent lymphomas', 'follicular lymphoma'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive lymphomas'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['DLBCL', 'diffuse large B-cell lymphoma'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['mantle cell lymphoma', 'MCL'] @entity978 :: ('MESH:D006689', 'Disease') :: ['Hodgkin lymphomas'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine']
@entity1892 :: (MESH:D016393,Disease) :: ['B-cell non-Hodgkin lymphomas']
